May Agenda

Improving the Lives of Patients with Schizophrenia

This educational activity will provide updates on current and emerging pharmacological strategies for optimizing outcomes in patients with schizophrenia. Presentations will compare available dopamine receptor-targeting antipsychotics and discuss utilizing long-acting injectables to improve adherence. In addition, emerging non-dopamine receptor treatments that may improve positive and negative symptoms without high side effects risk will be explored. The overarching goal is to enable providers to collaborate with patients in implementing individualized, evidence-based antipsychotic regimens to improve symptoms and quality of life.

All sessions will be held in Pacific Time (PT).

Saturday, May 18, 2024

7:00 am - 8:00 am

In the Present: Optimizing Treatment for Patients with Schizophrenia

Rona Hu, MD and Desiree M. Matthews, PMHNP-BC

Over the past few years, several new dopamine/serotonin receptor antagonists and partial agonists (aka “antipsychotics”) have become available for the treatment of schizophrenia. During this presentation, Desiree Matthews and Dr. Rona Hu will discuss the hypothesized neuropathology of schizophrenia as well as the mechanism by which dopamine/serotonin receptor-acting treatments may work to improve psychosis (as well as causing side effects). Additionally, strategies for optimizing treatment for the individual patient with schizophrenia (including use of long-acting injectables) will be explored.

8:00 am - 9:00 am

Industry Session^†: Rethinking Systems in Schizophrenia: Acetylcholine and Muscarinic Receptors

Leslie Citrome, MD, MPH

This exciting and interactive program will introduce the roles of acetylcholine and muscarinic receptors in schizophrenia, explore how this evolving science builds on our understanding of the pathophysiology of schizophrenia, and discuss what this means for us as providers, and for our patients.

Sponsored by Bristol Myers Squibb

9:00 am – 9:05 am

Break

9:05 am – 9:35 am

Poster Session^†: Switching Patients with Schizophrenia to TV-46000, a Long-Acting Subcutaneous Antipsychotic, From Risperidone Microspheres (R064766): An Exploration of Population Pharmacokinetic-Based Strategies

Jonathan M. Meyer, MD

This presentation describes population pharmacokinetic modeling that characterizes dosing conversions and switching strategies from R064766 (a once-every-2-weeks intramuscular formulation of risperidone microspheres) to TV-46000 (a once-monthly or once-every-2-months long-acting subcutaneous antipsychotic formulation of risperidone).

Sponsored by Teva Pharmaceuticals USA, Inc.

9:35 am - 10:50 am

In the Future: Update on Emerging Strategies to Ameliorate Positive, Negative, and Cognitive Symptoms of Schizophrenia

Jonathan M. Meyer, MD

As our understanding of the neurocircuitry involved in schizophrenia evolves, there is growing interest and research in tempering deviant dopamine levels in key brain areas by modulating upstream targets that affect downstream dopaminergic neurotransmission. In this presentation, Dr. Jonathan Meyer will discuss some of the emerging non-dopamine D2 blocking strategies that may ameliorate both positive and non-positive symptoms of schizophrenia as well as providing an update on the status of in-development agents being studied for the treatment of schizophrenia.

10:35 am - 11:00 am

Live Panel Q&A

Rona Hu, MD, Desiree M. Matthews PMHNP-BC, and Jonathan M. Meyer, MD

^†The content of all non-CME/CE events (Industry Symposia, Disease State Sessions, and Poster Sessions) and the views expressed therein are those of the presenting entity and not of NEI. These events are not part of the scientific program and do not provide CME/CE credit. By opening a non-CME/CE event, the attendee opts in to receive follow-up information from the commercial sponsor.

Program Faculty

Rona Hu, MD

Clinical Professor, Department of Psychiatry and Behavioral Sciences; Medical Director, Acute Psychiatric Inpatient Unit; Stanford Medical Center, Stanford University School of Medicine, Stanford, CA

Dr. Rona J. Hu received her medical degree in 1990 from the University of California, San Francisco School of Medicine, and completed her residency at the University of California, San Francisco Medical Center in 1994. She received her board certification in psychiatry in 1995 from the American Board of Psychiatry and Neurology.

Dr. Hu completed two fellowships while at the National Institutes of Health (NIH) from 1994-1998. She completed the PRAT (Pharmacology Research Associate Training) program from 1994-1996, and a schizophrenia research fellowship from 1996-1998.

Dr. Hu received the 2016 APA Nancy Roeske award for Excellence in Medical Student Education, the 2017 Faculty Award from Stanford University's Asian American Activities Center, and the 2017 Community Engagement Award from Stanford Department of Psychiatry.

Desiree M. Matthews, PMHNP-BC

Psychiatric-Mental Health Nurse Practitioner, Advanced Practice Clinical Liaison Monarch, Charlotte, NC Stanley, North Carolina

Desiree Matthews is a board-certified psychiatric nurse practitioner with expertise in treating patients living with severe mental illness. Beyond clinical practice, Desiree has provided leadership in advocating for optimal outcomes and elevating healthcare provider education. Desiree is the founder and owner of Different MHP, a telepsychiatry practice founded with the mission of providing affordable, accessible precision focused, integrative psychiatry to patients through a rich and comprehensive mentorship of the health care providers within the company.

Jonathan M. Meyer, MD

Voluntary Clinical Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA

Dr. Jonathan Meyer is a Voluntary Clinical Professor of Psychiatry at University of California, San Diego, and a Distinguished Life Fellow of the American Psychiatric Association. Dr. Meyer is a graduate of Stanford University and Harvard Medical School, finished his adult psychiatry residency at LA County-USC Medical Center and completed fellowships there in Consultation/Liaison Psychiatry and Psychopharmacology Research. Dr. Meyer has teaching duties at UC San Diego and the Balboa Naval Medical Center in San Diego and is a consultant to the first episode psychosis program at Balboa NMC.

Dr. Meyer has lectured and published extensively on psychopharmacology and is the sole author of the chapter on the Pharmacotherapy of Psychosis and Mania for the last 3 editions of Goodman & Gilman's The Pharmacological Basis of Therapeutics. Along with Dr. Stephen Stahl he is co-author of The Clozapine Handbook published in 2019, The Clinical Use of Antipsychotic Plasma Levels published in 2021, and The Lithium Handbook published in 2023.